Literature DB >> 17055123

Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups.

Brendon Y Chua1, Weiguang Zeng, Yuk Fai Lau, David C Jackson.   

Abstract

We have previously shown that incorporating the lipid moiety dipalmitoyl-S-glyceryl cysteine (Pam2Cys) into peptide structures effectively adjuvants otherwise weak immunogens. In this study lipopeptides based on luteinising hormone releasing hormone (LHRH) as a B cell epitope, [B], were synthesised in tandem with a 17-residue T-helper epitope, [T], derived from the fusion protein of the morbillivirus canine distemper virus. In this way vaccine candidates with the structure [T]-[B] were produced. These peptides were then lipidated with different diacylated moieties. The acyl moieties used were: palmitic acid (C16) to give Pam2Cys, stearic acid (C18) to give Ste2Cys, lauric acid (C12) to give Lau2Cys and octanoic acid (C8) to give Oct2Cys. We compared the immunogenicities of these simple lipopeptides in BALB/c mice by measuring their ability to induce anti-LHRH antibodies and found that immunogenicity was dependent on the length of the alkane chains of the incorporated lipid moieties with the hierarchy C16=C18>C12>C8. The antibody levels elicited by the lipopeptides also correlated with their ability to inhibit the reproductive capability of female mice in fertility trials. Furthermore, the C16 lipopeptide was the most effective in activating dendritic cells, measured by up regulation of surface MHC Class II molecules, and also in activating NF-kappaB in a Toll-like receptor-2 (TLR2)-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055123     DOI: 10.1016/j.vaccine.2006.07.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.

Authors:  Weiguang Zeng; Kylie J Horrocks; Gorjana Robevska; Chinn Yi Wong; Kristy Azzopardi; Marija Tauschek; Roy M Robins-Browne; David C Jackson
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 2.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

3.  Current Prospects in Peptide-Based Subunit Nanovaccines.

Authors:  Prashamsa Koirala; Sahra Bashiri; Istvan Toth; Mariusz Skwarczynski
Journal:  Methods Mol Biol       Date:  2022

4.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

Review 5.  Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.

Authors:  Matthew Black; Amanda Trent; Matthew Tirrell; Colleen Olive
Journal:  Expert Rev Vaccines       Date:  2010-02       Impact factor: 5.217

Review 6.  The use of plants for the production of therapeutic human peptides.

Authors:  Chiara Lico; Luca Santi; Richard M Twyman; Mario Pezzotti; Linda Avesani
Journal:  Plant Cell Rep       Date:  2012-01-05       Impact factor: 4.964

7.  Characterization of a branched lipopeptide candidate vaccine against influenza A/Puerto Rico 8/34 which is recognized by human B and T-cell immune responses.

Authors:  Liz Samayoa; Francisco Diaz-Mitoma; Ali Azizi
Journal:  Virol J       Date:  2011-06-16       Impact factor: 4.099

8.  Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.

Authors:  Mehfuz Zaman; Abu-Baker M Abdel-Aal; Yoshio Fujita; Karen S M Phillipps; Michael R Batzloff; Michael F Good; Istvan Toth
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

9.  Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.

Authors:  Brendon Y Chua; Douglas Johnson; Amabel Tan; Linda Earnest-Silveira; Toshiki Sekiya; Ruth Chin; Joseph Torresi; David C Jackson
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

10.  Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Pele Chong; Shih-Jen Liu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.